BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19924813)

  • 1. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
    Labrinidis A; Hay S; Liapis V; Findlay DM; Evdokiou A
    Int J Cancer; 2010 Jul; 127(2):345-54. PubMed ID: 19924813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
    Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
    Liu M; Sun LL; Li YJ; Li HY; Zhang J; Li BH; Ye ZM
    Int Immunopharmacol; 2015 Sep; 28(1):160-7. PubMed ID: 26071219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
    Koto K; Horie N; Kimura S; Murata H; Sakabe T; Matsui T; Watanabe M; Adachi S; Maekawa T; Fushiki S; Kubo T
    Cancer Lett; 2009 Feb; 274(2):271-8. PubMed ID: 18986762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
    Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
    Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
    Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
    Heymann D; Ory B; Blanchard F; Heymann MF; Coipeau P; Charrier C; Couillaud S; Thiery JP; Gouin F; Redini F
    Bone; 2005 Jul; 37(1):74-86. PubMed ID: 15894525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
    Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
    Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model.
    Dass CR; Choong PF
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3263-70. PubMed ID: 18089720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
    Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
    Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
    J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
    Lamoureux F; Ory B; Battaglia S; Pilet P; Heymann MF; Gouin F; Duteille F; Heymann D; Redini F
    Int J Cancer; 2008 Feb; 122(4):751-60. PubMed ID: 17960623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
    Yoshiyama A; Morii T; Ohtsuka K; Ohnishi H; Tajima T; Aoyagi T; Mochizuki K; Satomi K; Ichimura S
    Anticancer Res; 2016 Feb; 36(2):625-31. PubMed ID: 26851017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
    Tannehill-Gregg SH; Levine AL; Nadella MV; Iguchi H; Rosol TJ
    Clin Exp Metastasis; 2006; 23(1):19-31. PubMed ID: 16715352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
    Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
    Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.